Vinflunine is a pharmacologically active or chemically reactive compound used in pharmaceutical manufacturing as an active ingredient, synthetic intermediate, or process reagent, requiring toxicological characterisation to establish protective occupational exposure limits. Available data from in vitro and in vivo studies are evaluated in a weight-of-evidence assessment to identify the critical study, the most sensitive adverse effect endpoint, and the applicable NOAEL or LOAEL that serves as the point of departure for PDE calculation. Data gaps are addressed through read-across from structurally related compounds, (Q)SAR predictions, or application of TTC defaults where scientifically justified.
Health-based exposure limits for Vinflunine require formal periodic review as new toxicological evidence, clinical safety data, or regulatory agency assessments become available. Pharmaceutical manufacturers are expected to maintain a defined review cycle—typically every 3–5 years or triggered by significant new findings—and to update OEL, PDE, and